May 2017 - Southern California - Epitracker Selected as San Diego Venture Group 2017 Cool Company
It is official...we are cool! Epitracker has been announced as a 2017 Cool Company by the San Diego Venture Group (SDVG). With over 160 applicants, we are proud to be among 36 companies selected by SDVG and touted to VCs as 'one of the fastest growing , exciting startups in Southern California'. Look forward to the many SDVG events ahead!
May 2017 - San Diego - Epitracker Raises $1M
Epitracker successfully raised $1M to advance development of its lipid-based therapeutic platform to prevent, manage, and treat cardiometabolic diseases. A big thanks to our investors! Expect big advances in 2017...
April 2017 - San Diego - Epitracker's CEO Nominated for Athena's 2017 Pinnacle Award
Stephanie Venn-Watson, Epitracker's co-founder and CEO, was nominated for Athena's 2017 Pinnacle Award, Individual in Life Science.
April 2017 - San Diego - Epitracker's New Digs at BioLabs San Diego
Epitracker is enjoying our new laboratory space at BioLabs San Diego where our Director of Research, Dr. Rick Lumpkin, and consulting medicinal chemist, Dr. John Reiner, are busy working on our lead therapeutic, ETI-101. Thank you, BioLabs!
April 2017 - San Diego - Epitracker Co-Founder and CMO Presents at VetsinTech San Diego
Eric Venn-Watson participated in a panel at the UCSD Rady School of Management focused on veteran entrepreneurship. Military veterans in San Diego heard Eric's stories about his transition from active duty to biotech.
March 2017 - San Diego - Epitracker Establishes Cooperative Research & Development Agreement with U.S. Navy
Dolphins have emerged as innovative and relevant patient populations for human health. Epitracker is actively collaborating with the U.S. Navy to support advanced discovery research aimed to continually improve both Navy dolphin and human health. This cooperative agreement focuses on discovering innovative therapeutics in the areas of anti-aging, cardiometabolic diseases, neurodegenerative diseases, and skin repair.
March 2017 - San Diego - Welcome, Dr. Rick Lumpkin, Our New Director of Research
We welcome Dr. Lumpkin to the core Epitracker team this month as our Director of Research. Rick Lumpkin, Ph.D., has 30 years of broad based experience, including synthetic chemistry, in early stage biotechnology companies. Most recently he was a Sr. Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. He was an original member of the team that spun off Portola Pharmaceuticals from Millennium Pharmaceuticals. Earlier in his career, he held positions of increasing responsibility as a synthetic chemist at COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.
January 2017 - San Diego - Epitracker welcomes Michael Berthelot to Business Advisory Board
We are honored to announce the addition of Michael Berthelot to our BAB. Mike has vast experience in corporate governance and ethics, having served on more than thirty public, private, and non-for-profit boards over the past thirty years. Mike founded Cito Capital Corporation, teaches at UCSD Rady School of Management and has been awarded Director of the Year by the Corporate Directors Forum.
December 2016 - Los Angeles - Epitracker is Featured Presentation at Annual Faculty Dinner for World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
We were honored to present our novel lipid-based therapeutic platform and other dolphin-based discoveries relevant to this prestigious cardiometabolic community. Thank you, WCIRDC...it was a fantastic meeting!
June 2016 - San Diego Startup Week is Here! Co-Founders Eric & Stephanie Venn-Watson on Seed Funding Panel
To help kick off the first day of San Diego's Startup Week, Epitracker's co-founders, Eric & Stephanie Venn-Watson participated in a panel discussion, "Guiding Seed Stage Founding Team in the Health and Wellness Space." Enjoy the week, fellow entrepreneurs!
May 2016 - San Diego - Epitracker Welcomes Magda Marquet and Rick Lumpkin to Business Advisory Board
We are honored to announce the addition of Dr. Magda Marquet and Dr. Rick Lumpkin to our BAB. Magda, Founder and Co-Chair of Althea Technologies, Inc., was recently inducted into the CONNECT Entrepreneur Hall of Fame. We are excited to have her start-up and industry expertise. Rick is bringing his critical knowledge in synthetic chemistry and drug development to the Epitracker table. Welcome, Magda and Rick!
April 2016 - Los Angeles - Epitracker Highlighted at LA BioMed Innovation Showcase 2016. Epitracker pitched at LA BioMed's Innovation Showcase on April 28th, while enjoying our expanded our supportive network in Southern California.
April 2016 - San Diego - Epitracker Welcomes Anita Busquets to Business Advisory Board. Anita Busquets, M.B.A. is a highly experienced, start-up executive who has served in a wide range of operating and financial management roles. Welcome, Anita!
April 2016 - San Diego - Epitracker Co-Founder on Rady School of Management Entrepreneurship panel
Eric participated in a panel discussing entrepreneurship in San Diego.
April 2016 - San Diego - Epitracker CEO and Co-Founder Part of Women in Business Series at UCSD
Stephanie participated in an interactive panel with fellow women entrepreneurs in San Diego. This fun event was hosted by The Entrepreneur Challenge.
March 2016 - San Diego - Epitracker Welcomes Wendy Johnson to Business Advisory Board
Joining Epitracker's BAB, Wendy S. Johnson is a venture partner with ProQuest Investments, and the CEO of two San Diego-based companies, Aires Pharmaceuticals and Palkion. She has broad experience in the establishment and operations of venture-backed life science companies. Welcome, Wendy!
February 2016 - San Diego - Epitracker Raises Seed Funding
Epitracker successfully raised its first round of seed funding to support development of ETI-101 as an oral therapeutic to prevent, manage, and treat metabolic syndrome.
January 2016 - San Diego - Epitracker Welcomes Greg Horowitt to Board of Directors
Welcome, Greg! Greg Horowitt is a Partner with KAI Capital Group, Founding Partner & Managing Director for T2 Venture Capital, and Co-Founder and Senior Advisor of Global CONNECT. Greg has personally advised and mentored more than 200 companies. He is the co-author of the bestselling book, The Rainforest: the Secret to Building the Next Silicon Valley.
January 2016 - San Diego - Epitracker LLC Converts to Epitracker Inc.
As part of our planned growth within the biopharmaceutical industry, Epitracker has converted from a limited liability corporation to a Delaware-based C corporation. What a great way to kick off an exciting new year!
December 2015 - San Diego - Epitracker Expands its IP Portfolio
Through a licensing agreement with the U.S. Navy (Space and Naval Warfare Systems Center Pacific), Epitracker has acquired exclusive licensing rights to five pending U.S. patents and four international patents related to products that aim to detect, prevent, and treat metabolic disorders.
September 2015 - Epitracker Presented as Hot Topic for Venture Summit 2015
Epitracker's new approach to tracking diseases and finding cures in nature was presented as a prestigious Hot Topic for Venture Summit 2015 in San Diego on September 25th.
July 2015 - Epitracker's Co-Founder Discovers Molecule that May Prevent Type 2 Diabetes
In a PLOS ONE article released this month, Dr. Stephanie Venn-Watson and her team reported the discovery of a molecule present in some fish that was associated with normalizing insulin, glucose, and triglycerides in dolphins. These findings are receiving national media attention in the Union Tribune, Tech Times, and TakePart, as well as international coverage in India, U.K., and Germany. Listen to NPR Science Friday's podcast and KPBS Evening Edition's interview on this discovery. Learn more.
July 2015 - Epitracker Acquires Exclusive License from U.S. Navy for Novel Use of Fatty Acid to Treat Prediabetes
An exciting launch to Epitracker's new initiative to find cures, it has acquired an exclusive license from the U.S. Navy to commercialize and market a novel fatty acid to prevent, alleviate, treat, and cure hyperferritinemia, metabolic syndrome, and their associated complications.
July 2015 - Landmark Settlement Proposed by BP for Deepwater Horizon Oil Spill
Weeks following publication of key studies led by Epitracker. University of Illinois, and the U.S. Government documenting the likely effects of oil exposure to wild dolphin deaths in the Gulf of Mexico, BP has offered an $18.7B settlement, including support to restore dolphin health.
June 2015 - Epitracker Invited as Hot Topic for San Diego Venture Summit 2015
Epitracker's new approach to tracking diseases and finding cures in nature has been invited as a prestigious Hot Topic for Venture Summit 2015 in San Diego on September 25th.
April & May 2015 - 5-Year Anniversary of the Deepwater Horizon Oil Spill: Epitracker Co-Founder Answers Media's Questions about Gulf Dolphins
Five years following the Deepwater Horizon oil spill and upon the release of key findings in part from Epitracker's funded investigation, Scientific American, New York Times. CBS News and others covered scientific studies related to the potential impacts of the oil spill on dolphins in the Gulf of Mexico.
April 2015 - Epitracker Joins Biocom
Proud to be part of Southern California's innovative life sciences community, Epitracker is now an official member of Biocom.
April 2015 - Epitracker Welcomes Dr. John Contreras as a Biocom Veteran Intern
As part of Biocom's Military Veteran Initiative, Epitracker welcomes Dr. John Contreras! Dr. Contreras is serving as Epitracker's marketing consultant to help implement one of our exciting and promising new marketing and commercialization plans.
March 2015 - Epitracker Acquires License for Novel Use of Fatty Acid to Stem Diabetes and Hyperferritinemia
An exciting launch to Epitracker's new initiative to find cures, it has acquired a license to commercialize and market a novel fatty acid to prevent, alleviate, treat, and cure metabolic syndrome and hyperferritinemia, as well as their associated conditions.
March 2015 - Epitracker Co-Founder & CEO Presents at J&J IN(novation): Powerful Ideas Series
If you had 10 minutes to change business models, the lives of patients and, ultimately, the world – what would you do with it? As part of the J&J (IN)novation: Powerful Ideas Series, Dr. Stephanie Venn-Watson presented how bringing together the best minds from human medicine, veterinary medicine, and laboratory and field science - to help dolphins - may help to stem the global diabetes pandemic. This exciting series took place at the CALBIO 2015 meeting in San Francisco on March 2, 2015.
February 2015 - Epitracker Leads Key Publication on Deepwater Horizon Oil Spill & Potential Dolphin Impacts
An Epitracker-led study investigating demographic clusters of wild dolphin strandings before and since the Deepwater Horizon oil spill has been published in PLOS ONE. Read the L.A. Times and New York Times articles covering Dr. Stephanie Venn-Watson and the large investigative team's key findings.
December 2014 - Cover Story for Biocom's Lifelines Magazine Features Innovative Science with Epitracker Co-Founder
Lifelines magazine featured Epitracker's CEO's Dolphins & Diabetes Program with the National Marine Mammal Foundation. In the cover story entitled, 'From Project to Passion,' Dr. Stephanie Venn-Watson shares the value and importance of applying a One Health approach to build multidisciplinary teams who can help to better prevent, manage, and treat diseases in both dolphins and humans.
December 2014 - Epitracker Co-Founder on Committee Panel for San Diego's Economic Development Corporation
Dr. Eric Venn-Watson participated in a panel to discuss the benefits and costs of starting and keeping businesses in San Diego. Dr. Venn-Watson's fellow panel members included the President & CEO of Sony Online Entertainment and Chairman of Proficio, Inc.
November 2014 - Epitracker Co-Founder Featured at Biocom's Annual Dinner
Biocom, Southern California's leading member organization for life science companies and institutions, featured Epitracker's CEO, Dr. Stephanie Venn-Watson, at their annual dinner themed, 'Making Waves'. Over 700 attendees from San Diego's leadership community listened to Dr. Venn-Watson's talk on the National Marine Mammal Foundation's Dolphins & Diabetes Project, including their most innovate science to improve dolphin health while also translating into exciting, new ways to prevent and cure diabetes in people.
June 2014 - Epitracker Adds New Focus Area - Finding Cures
Thanks to support from BIO International and Biocom, Epitracker has added a new focus area of Finding Cures. This exciting area was due to the life science community's recognition of the high and untapped potential of finding cures by investigating disease and health in novel, natural animal populations.
September 2014 - NOAA Contract Awarded to Epitracker to Aid in Marine Mammal Health Monitoring and Analysis Program (MMHMAP)
The Marine Mammal Commission is partnering with NOAA's Marine Mammal Health and Stranding Response Program and others to develop a National Marine Mammal Health Monitoring and Analysis Program (MMHMAP) which will allow easy tracking of marine mammal diseases detected by location, time, and species. Epitracker has been contracted to help develop MMHMAP's strategic plan, facilitate workshops, and implement the national program.
January 2014 - National Resource Damage Assessment of Deepwater Horizon Oil Spill Adds Epitracker to Team
As part of a multi-year investigation of potential impacts of the Deepwater Horizon oil spill on marine mammal health in the Gulf Of Mexico, Epitracker has been awarded a subcontract with Industrial Economics. Epitracker will play a lead role among the investigative team to evaluate potential associations between wild dolphin strandings, disease states, the oil spill, and other potential contributors.
June 2013 - Epitracker becomes a Limited Liability Corporation
This month, Epitracker changed from a sole proprietorship to a limited liability corporation.
August 2012 - NOAA Contract to Support Brucella Surveillance and Strategic Planning in Alaska Won by Epitracker
Epitracker was awarded a 2-year contract with NOAA to help establish a national Brucella surveillance program in wild marine mammals; facilitate a workshop in Alasksa; and help develop a strategic plan for monitoring and investigating marine mammal unusual mortality events in Alaska.
March 2012 - Epitracker Successfully HUBZone Certified by U.S. Small Business Administration
Epiracker successfully acquired HUBZone Certification and is now eligible for set aside HUBZone government contracts.
January 2011 - Epitracker Wins Prime Contract to Aid in Gulf of Mexico Dolphin Unusual Mortality Event Investigation
In response to an ongoing cetacean unusual mortality event in the northern Gulf of Mexico, Epitracker won a NOAA contract to help characterize, track, and investigate potential causes of increased dolphin mortalities.
February 2010 - Epitracker Co-Founder & CEO Featured on National Public Radio's Science Friday
During a special National Public Radio's Science Friday edition in front of a live audience, Epitracker's Co-Founder, Dr. Stephanie Venn-Watson, discussed with host Ira Flatow, the shared benefits of studying diseases in both humans and dolphins. Click here to listen to this show.
February 2010 - Epitracker Co-Founder & CEO Receives Positive International Attention for Discovery
The American Association for the Advancement of Science selected the scientific discovery from Epitracker's CEO, Dr. Stephanie Venn-Watson for a formal press conference during their annual meeting in San Diego, California. Dr. Venn-Watson presented her discovery of a possible natural diabetes off switch in bottlenose dolphins through her work at the National Marine Mammal Foundation. This exciting discovery received positive, international attention, including BBC, National Geographic, and CBS.
June 2009 - Trademark for Epitracker Acquired
Epitracker has trademarked its name through the U.S. Patent and Trademark Office.
October 2009 - Epitracker Wins Subcontract with Earth Resources Technology, Inc. for National Oceanic and Atmospheric Administration (NOAA)
Epitracker has been awarded a 2-year NOAA subcontract to prioritize marine mammal pathogens, facilitate a workshop and develop a strategic plan to prioritize contaminants of concern for the International Whaling Commission, facilitate workshops and develop strategic plans for sea turtle health monitoring and marine mammal Coxiella surveillance, and to conduct retrospective studies to assess perinatal dolphin strandings in the Gulf of Mexico.
May 2008 - Epitracker Launched as Data Analytics Company
Epitracker, founded by Dr. Stephanie Venn-Watson and Dr. Eric Venn-Watson, was launched this month. Epitracker was born from the power of analytics, the founders' passion for discovery, and the growing demand for evidence-based medicine. Epitracker is a woman owned-small business based in San Diego, California.
In the News
Dolphin Health Study Discovers Saturated Fat with Metabolic Benefits
In an effort to better understand dolphin nutrient needs, Dr. Stephanie Venn-Watson discovered a natural molecule that may help to reverse prediabetes. Epitracker is taking the next steps toward developing EpitRx as a therapeutic to treat metabolic syndrome.
Making Breakthroughs Through One Health: J&J Innovations Powerful Ideas Series
If you had 10 minutes to change business models, the lives of patients and, ultimately, the world – what would you do with it? As part of the J&J (IN)novation: Powerful Ideas Series, Epitracker's Co-Founder, Dr. Stephanie Venn-Watson, presented how bringing together the best minds from human medicine, veterinary medicine, and laboratory and field science - to help dolphins - may help stem the global diabetes pandemic. This exciting series took place at the CALBIO 2015 meeting in San Francisco on March 2, 2015.
Epitracker Presented at 2016 L.A. BioMed Innovation Showcase
L.A. BioMed Innovation Showcase
Thursday, April 28 2016
Epitracker was an invited presenter at LA BioMed’s 2016 Innovation Showcase. Entrepreneurs, investors, BD executives with established companies, as well as prominent scientists from these premier academic institutions attended presentations featuring the latest innovations in therapeutics and medical devices from start-ups, including Epitracker.
Epitracker Presented at Venture Summit 2015: Hot Topic
Venture Summit 2015
Friday, September 25 2015
MANCHESTER GRAND HYATT
1 Market Place
San Diego, California, USA, 92101
Epitracker's novel approach to finding cures was presented as a Hot Topic at Venture Summit 2015! San Diego Venture Group's Venture Summit is the largest annual gathering of VCs outside of Silicon Valley. More than 500 in the venture capital community attended this meeting.